Frontiers in Cardiovascular Medicine (Apr 2022)

Risk Estimation for Infection in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Development and Validation of a Predictive Score

  • Yuanhui Liu,
  • Yuanhui Liu,
  • Litao Wang,
  • Litao Wang,
  • Pengyuan Chen,
  • Yining Dai,
  • Yining Dai,
  • Yaowang Lin,
  • Wei Chen,
  • Zhengrong Xu,
  • Lihuan Zeng,
  • Lihuan Zeng,
  • Hualin Fan,
  • Hualin Fan,
  • Ling Xue,
  • Ling Xue,
  • Simin Liu,
  • Jiyan Chen,
  • Jiyan Chen,
  • Ning Tan,
  • Ning Tan,
  • Ning Tan,
  • Pengcheng He,
  • Pengcheng He,
  • Pengcheng He,
  • Chongyang Duan

DOI
https://doi.org/10.3389/fcvm.2022.845307
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundInfection during hospitalization is a serious complication among patients who suffered from acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI); however, there are no suitable and accurate means to assess risk. This study aimed to develop and validate a simple scoring system to predict post-AMI infection in such patients.MethodsAll patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI consecutively enrolled from January 2010 to May 2016 were served as derivation cohort, and those from June 2016 to May 2018 as validation cohort, respectively. The primary endpoint was post-AMI infection during hospitalization, and all-cause death and major adverse cardiovascular events (MACE) were considered as secondary endpoints. The simplified risk model was established using logistic regression. The area under the receiver operating curve and calibration of predicted and observed infection risk were calculated.ResultsA 24-point risk score was developed, with infection risk ranging from 0.7 to 99.6% for patients with the lowest and highest score. Seven variables including age, Killip classification, insulin use, white blood cell count, serum albumin, diuretic use, and transfemoral approach were included. This model achieved the same high discrimination in the development and validation cohort (C-statistic:0.851) and revealed adequate calibration in both datasets. The incidences of post-AMI infection increased steadily across risk score groups in both development (1.3, 5.1, 26.3, and 69.1%; P < 0.001) and validation (1.8, 5.9, 27.2, and 79.2%; P < 0.001) cohort. Moreover, the risk score demonstrated good performance for infection, in-hospital all-cause death, and MACE among these patients, as well as in patients with the non-ST-elevation acute coronary syndrome.ConclusionThis present risk score established a simple bedside tool to estimate the risk of developing infection and other in-hospital outcomes in patients with STEMI undergoing PCI. Clinicians can use this risk score to evaluate the infection risk and subsequently make evidence-based decisions.

Keywords